External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory
The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
| Condition(s) | Diffuse Large B Cell Lymphoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma. |
| Who can participate | Inclusion Criteria: * Participant aged ≥ 18 years * Disease criteria: * Histologically confirmed large b-cell lymphoma (LBCL), including DLBCL not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma with: * Relapsed or refractory disease with at least 2 prior systemic therapies * Must be a candidate for radiation therapy up to 20 Gy. Radiation therapy to up to 3 lesions will be permitted. * Must have at minimum two sites of evaluable disease per Lugano 2014, including one site that will not be irradiated as part of this study and has not received radiation therapy in the past. * ECOG Performance Status ≤ 3 * Adequate organ function as defined as --Hematologic: * Absolute neutrophil count ≥ 1000/mm3 (Note: Use of G-CSF is permitted) * Platelet |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Utah |
| Locations | Salt Lake City, Utah, United States |
| Start date | 2026-06-01 |
| NCT ID | NCT07528352 |
| Official listing | https://clinicaltrials.gov/study/NCT07528352 |